Compare Citius Pharmaceuticals Inc (CTXR) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs ON Holding AG — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while ON Holding AG trades at $38.33 (market cap $12.58B). The key difference: ON Holding AG is far larger — about 859.3× Citius Pharmaceuticals Inc's market cap, and ON Holding AG is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | ONON | |
|---|---|---|
Market Cap | $14.64M | $12.58B |
Sector | Health | Technology |
52-Week High | $1.82 | $54.24 |
52-Week Low | $0.53 | $31.88 |
Enterprise Value | $10.86M | $11.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
ONON trades at $37.92, down 1.61% today, with a bullish technical trend and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.47 exceeding expectations. Revenue reached $3.01B in 2025, with gross margins at 63.88% and net income of $203.70M. Analyst sentiment is overwhelmingly positive, with 76.92% recommending Buy and a consensus price target of $47.33.
Outlook remains favorable given robust growth and margin expansion, but risks include high valuation multiples and competitive pressures. The stock offers upside potential if execution continues, though investors should monitor earnings sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
